Gilde Healthcare bolsters its Private Equity team in Frankfurt office - Gilde Healthcare

Gilde Healthcare bolsters its Private Equity team in Frankfurt office

12 juli 2022
Utrecht (Nederland) en Frankfurt (Duitsland)

Dutch sector specialist Gilde Healthcare announces two new hires to its private equity team in Germany, following the recent close of its new €518m lower mid-market fund Gilde Healthcare Private Equity IV.

With the recruitment of Martin von Berg as Investment Manager and Lara Hilgert as Investment Analyst, the firm continues to expand its team in the region, following the arrival Robert Stein as Partner in 2021. Before joining Gilde Healthcare, Martin gained more than 5 years of private equity experience at 3i and Halder, where he was involved in healthcare services transactions. Martin started his career in the investment banking team of Bank of America in Frankfurt after graduating from the University of Mannheim with a MSc in Management. Lara joins Gilde Healthcare after finishing her MSc in Management at the London School of Economics. She successfully completed an internship at Gilde Healthcare last year and gained additional working experience at Roland Berger, Greenhill and PWC.

Gilde Healthcare completed four private equity transactions in Germany in the last 18 months and considers additional hires in the coming period.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.9 billion across two fund strategies: Private Equity and Venture&Growth. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers to pharma, medtech and healthcare. Gilde Healthcare’s Venture&Growth fund invests in therapeutics, medtech and healthtech in Europe and North America. Further information at www.gildehealthcare.com

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova...
9 oktober 2024

Gilde Healthcare company Adcendo announces IND clearance by FDA for the phase I/II study of ADCE-D01

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma (STS) subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate...
7 oktober 2024

GILDE HEALTHCARE COMPANY SYNEXA LIFE SCIENCES ACQUIRES ALDERLEY ANALYTICAL TO EXPAND BIOANALYSIS CAPABILITIES IN DRUG DEVELOPMENT

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning...
3 oktober 2024